Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudy Gunawan

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Regulatory Toxicology and Pharmacology : RTP|October 27, 2012
A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humansJustin G Teeguarden, Conrad J Housand, Jordan N Smith, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2023
Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumorsChaitali Passey, Jenna Voellinger, Leonid Gibiansky, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 28, 2011
Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposureJustin G Teeguarden, Antonia M Calafat, Xiaoyum Ye, et al.
European Journal of Clinical Pharmacology|December 10, 2015
No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjectsRosie Z Yu, Rudy Gunawan, Zhaoyang Li, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 3, 2025
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotinSummer Feng, Rudy Gunawan, Chaitali Passey, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Nucleic Acid Therapeutics|August 9, 2016
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in MonkeysRosie Z Yu, Rudy Gunawan, Noah Post, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Regulatory Toxicology and Pharmacology : RTP|October 27, 2012
A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humansJustin G Teeguarden, Conrad J Housand, Jordan N Smith, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2023
Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumorsChaitali Passey, Jenna Voellinger, Leonid Gibiansky, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 28, 2011
Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposureJustin G Teeguarden, Antonia M Calafat, Xiaoyum Ye, et al.
European Journal of Clinical Pharmacology|December 10, 2015
No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjectsRosie Z Yu, Rudy Gunawan, Zhaoyang Li, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 3, 2025
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotinSummer Feng, Rudy Gunawan, Chaitali Passey, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Nucleic Acid Therapeutics|August 9, 2016
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in MonkeysRosie Z Yu, Rudy Gunawan, Noah Post, et al.
Pageof 2